Leerink's David Risinger downgrades Bristol Myers to market perform and cuts his price target to $59, citing doubts on ...
Deisseroth, Hegemann and Nagel win the 2026 Nobel in medicine for optogenetics, the basis of Nanoscope's RP gene therapy ...
Epicrispr's epigenetic editor EPI-321 shows a 3% gain in muscle volume in FSHD patients at 6 months, alongside one case of ...
Vaxcyte's shares jumped 35% Monday morning after the company announced that its experimental pneumococcal vaccine VAX-31 met its key endpoints in a Phase 3 trial with adults, a major step in its quest ...
Alector licenses Parkinson's drug AL050 to Roche for $100M upfront and up to $1.17B in milestones, shares up 20%+.
Welcome back to another edition of Endpoints Weekly! It’s October 3rd, the day he asked me what day it was. “It’s October 3rd ...
FDA opens Office of Innovation and Clinical Trial Modernization within CDER, with Marie Bradley as acting director of the ...
The Harvard lab of David Sinclair discusses a chemical cocktail it named SL-100 which, delivered in pill form, restored ...
Juan Andres will come out of retirement to rejoin Moderna as COO on Oct. 5, bringing his intimate knowledge of the company as its Merck-partnered cancer vaccine gathers momentum in the clinic.
Clive Meanwell and John Maraganore's Corsera Health is developing a once-yearly siRNA shot to prevent heart disease in ...
The cash should give the Stockholm-based biotech a runway “well into 2029,” CEO Patrik Strömberg told Endpoints News in ...
Aviceda Therapeutics has shut down after AVD-104 failed a Phase 2b trial vs. Astellas' Izervay for geographic atrophy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results